130 related articles for article (PubMed ID: 23093687)
1. Incretin effect of glucagon-like peptide 1 receptor agonist is preserved in presence of ABCC8/SUR1 mutation in β-cell.
Bourron O; Chebbi F; Halbron M; Saint-Martin C; Bellanné-Chantelot C; Abed A; Charbit B; Magnan C; Lacorte JM; Hartemann A
Diabetes Care; 2012 Nov; 35(11):e76. PubMed ID: 23093687
[No Abstract] [Full Text] [Related]
2. ATP-sensitive potassium channels--neonatal diabetes mellitus and beyond.
Sperling MA
N Engl J Med; 2006 Aug; 355(5):507-10. PubMed ID: 16885555
[No Abstract] [Full Text] [Related]
3. Incretin effects on β-cell function, replication, and mass: the human perspective.
Garber AJ
Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S258-63. PubMed ID: 21525465
[No Abstract] [Full Text] [Related]
4. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.
Yashiro H; Tsujihata Y; Takeuchi K; Hazama M; Johnson PR; Rorsman P
J Pharmacol Exp Ther; 2012 Feb; 340(2):483-9. PubMed ID: 22106100
[TBL] [Abstract][Full Text] [Related]
5. [Incretin related agents for treatment of diabetes mellitus].
Miyagawa J; Miuchi M; Nanba M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
[No Abstract] [Full Text] [Related]
6. Mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism.
Gloyn AL; Siddiqui J; Ellard S
Hum Mutat; 2006 Mar; 27(3):220-31. PubMed ID: 16416420
[TBL] [Abstract][Full Text] [Related]
7. Successful transfer to sulfonylurea therapy in an infant with developmental delay, epilepsy and neonatal diabetes (DEND) syndrome and a novel ABCC8 gene mutation.
Zwaveling-Soonawala N; Hagebeuk EE; Slingerland AS; Ris-Stalpers C; Vulsma T; van Trotsenburg AS
Diabetologia; 2011 Feb; 54(2):469-71. PubMed ID: 21109997
[No Abstract] [Full Text] [Related]
8. Sulfonylurea receptor 1 mutations that cause opposite insulin secretion defects with chemical chaperone exposure.
Pratt EB; Yan FF; Gay JW; Stanley CA; Shyng SL
J Biol Chem; 2009 Mar; 284(12):7951-9. PubMed ID: 19151370
[TBL] [Abstract][Full Text] [Related]
9. Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion.
De León DD; Li C; Delson MI; Matschinsky FM; Stanley CA; Stoffers DA
J Biol Chem; 2008 Sep; 283(38):25786-93. PubMed ID: 18635551
[TBL] [Abstract][Full Text] [Related]
10. [The value of incretin based therapies].
Gallwitz B
Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
[No Abstract] [Full Text] [Related]
11. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a novel missense mutation, p.P1199L, in the ABCC8 gene.
Oztekin O; Durmaz E; Kalay S; Flanagan SE; Ellard S; Bircan I
J Perinatol; 2012 Aug; 32(8):645-7. PubMed ID: 22842804
[TBL] [Abstract][Full Text] [Related]
12. Congenital hyperinsulinism: marked clinical heterogeneity in siblings with identical mutations in the ABCC8 gene.
Kapoor RR; Flanagan SE; Ellard S; Hussain K
Clin Endocrinol (Oxf); 2012 Feb; 76(2):312-3. PubMed ID: 21851374
[No Abstract] [Full Text] [Related]
13. The common C49620T polymorphism in the sulfonylurea receptor gene (ABCC8), pancreatic beta cell function and long-term diabetic complications in obese patients with long-lasting type 2 diabetes mellitus.
Stefanski A; Majkowska L; Ciechanowicz A; Frankow M; Safranow K; Parczewski M; Pilarska K
Exp Clin Endocrinol Diabetes; 2007 May; 115(5):317-21. PubMed ID: 17516295
[TBL] [Abstract][Full Text] [Related]
14. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
15. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.
Proks P; Arnold AL; Bruining J; Girard C; Flanagan SE; Larkin B; Colclough K; Hattersley AT; Ashcroft FM; Ellard S
Hum Mol Genet; 2006 Jun; 15(11):1793-800. PubMed ID: 16613899
[TBL] [Abstract][Full Text] [Related]
16. The common C49620T polymorphism in the sulfonylurea receptor gene SUR1 (ABCC8) in patients with gestational diabetes and subsequent glucose metabolism abnormalities.
Molęda P; Bińczak-Kuleta A; Homa K; Safranow K; Celewicz Z; Syrenicz A; Stefański A; Fronczyk A; Majkowska L
Exp Diabetes Res; 2012; 2012():712617. PubMed ID: 22927833
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment of diabetes caused by activating ABCC8/SUR1 mutation with glimepiride.
Karges B; Schnur D; Ellard S; Kentrup H; Karges W
Diabet Med; 2012 May; 29(5):692-3. PubMed ID: 21992555
[No Abstract] [Full Text] [Related]
18. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism.
Light PE; Manning Fox JE; Riedel MJ; Wheeler MB
Mol Endocrinol; 2002 Sep; 16(9):2135-44. PubMed ID: 12198249
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of KATP hyperactivity and sulfonylurea tolerance due to a diabetogenic mutation in L0 helix of sulfonylurea receptor 1 (ABCC8).
Babenko AP; Vaxillaire M
FEBS Lett; 2011 Nov; 585(22):3555-9. PubMed ID: 22020219
[TBL] [Abstract][Full Text] [Related]
20. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
Briones M; Bajaj M
Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
